Stocktoria
Pluri Inc. PLUR
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2007-12-10
Pluri Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $1.3M | $326,000 | $287,000 | $234,000 | — |
| Gross profit | $654,000 | $322,000 | $278,000 | $234,000 | — |
| R&D expense | $12.9M | $12.4M | $15.7M | $24.6M | $30.5M |
| Operating income | -$22.2M | -$22.2M | -$27.2M | -$41.6M | -$50.6M |
| Interest expense | — | — | $843,000 | $887,000 | $78,000 |
| Income tax | -$5,000 | — | — | — | — |
| Net income | -$22.6M | -$20.9M | -$28.3M | -$41.2M | -$49.9M |
| EPS (diluted) | $-3.56 | $-3.99 | $-6.24 | $-1.28 | $-1.77 |
| Operating cash flow | -$18.2M | -$18.0M | -$22.9M | -$36.5M | -$30.9M |
| Free cash flow | -$19.8M | -$18.3M | -$23.1M | -$36.8M | -$31.3M |
| Cash & equivalents | $5.9M | $6.8M | $5.4M | $9.8M | $31.2M |
| Total assets | $38.7M | $39.5M | $50.8M | $68.1M | $93.5M |
| Shareholders' equity | -$6.8M | $5.4M | $15.3M | $32.2M | $57.2M |
Source: SEC EDGAR filings · CIK 0001158780 · as of 2025-06-30. Facts from filings plus Stocktoria's own computed scores — not investment advice.